<strong>Cadbury</strong><br />Charles Stanley upgraded Cadbury to &ldquo;Accumulate&rdquo; status. The launch of Fair Trade-certified Dairy Milk in the UK and Ireland could result in further share gains which would be a significant hurdle for competitors, it said. The broker also believes Cadbury can achieve its anticipated revenue growth and hit margin targets.<br /><br /><strong>Lancashire</strong><br />Execution Research continues to support insurer Lancashire as a core &ldquo;Buy&rdquo;. The broker believes there has been too much &ldquo;nit picking&rdquo; running up to results with regards to the company&rsquo;s Golf of Mexico energy cover, and believes Lancashire has significant ability to offset this among its core property, marine and other energy policies.<br /><br /><strong>Glaxosmithkline</strong><br />Charles Stanley cut estimates on pharmaceutical business GlaxoSmithkline to &ldquo;Hold&rdquo;. It said although the company&rsquo;s ability to deliver pandemic preparations for swine flu and sales of anti-viral Relenza look positive, these factors may be insufficient to counter the negative of margin lost from recent patent losses on key products.